HYPERCALCEMIA. Babak Tamizi Far MD. Assistant professor of internal medicine Al-zahra hospital, Isfahan university of medical sciences

Similar documents
Definition Elevated Adjusted Calcium > 2.6 mmol/l (adjusted for albumin), taken without using a cuff.

Definition Elevated Adjusted Calcium > 2.6 mmol/l (adjusted for albumin), taken without using a cuff.

Approach to a patient with hypercalcemia

HYPERCALCAEMIA 101 FOR THE INTERNIST

hypercalcemia of malignancy hyperparathyroidism PHPT the most common cause of hypercalcemia in the outpatient setting the second most common cause

BCCA Protocol Summary Guidelines for the Diagnosis and Management of Malignancy Related Hypercalcemia

Hypercalcemia. Hypercalcemia: When to Worry, When to Treat! Mineral Metabolism : A Short Course

Hypocalcemia 6/8/12. Normal value. Physiologic functions. Nephron a functional unit of kidney. Influencing factors in Calcium and Phosphate Balance

Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient

Calcium and Parathyroid Disorders

Symptom management: Hypercalcemia

WATER, SODIUM AND POTASSIUM

Dosage in renal impairment Kalcipos-D chewable tablets should not be used in patients with severe renal impairment.

Hypercalcemia. Brian Rose, M.D. Bozeman Health June 6, 2018

Hypercalcemia & Parathyroid Disorders. W. Reid Litchfield, MD, FACE, ECNU Desert Endocrinology

Southern Derbyshire Shared Care Pathology Guidelines. Primary Hyperparathyroidism

Neither activated charcoal nor whole bowel irrigation (WBI) is indicated in the routine management of acute or chronic lithium toxicity.

Clinical Approach to Hypercalcemia For the Primary Care Provider

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF THE PRODUCT CHARACTERISTICS

Investigations for Disorders of Calcium, Phosphate and Magnesium Homeostasis

Clinical biochemistry of calcium and vitamin D

CASE PRESENTATION. Kārlis Rācenis MD - Latvia

The parathyroid glands participate in the regulation

SUMMARY OF PRODUCT CHARACTERISTICS. One chewable tablet contains 1250 mg calcium carbonate (equivalent to 500 mg calcium).

Disclosure. Topic Outline. Calcium, Vitamin D, PTH Disorders. PTH/Calcium-Normal Physiology. I have nothing to disclose

SUMMARY OF PRODUCT CHARACTERISTICS

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory OSTOCALCIUM FORTE TABLETS

CALCIUM BALANCE. James T. McCarthy & Rajiv Kumar

Management of hypercalcemia of malignancy

SUMMARY OF THE PRODUCT CHARACTERISTICS

Natpara (parathyroid hormone) Prior Authorization with Quantity Limit Program Summary

"Asymptomatic" Hyperparathyroidism: Reasons for Parathyroidectomy

Draft Labeling Package Insert Not Actual Size. BRAINTREE LABORATORIES, INC. PhosLo Capsules (Calcium Acetate)

Oncological emergencies. Harmesh Naik, MD. Medical Oncology Hope Cancer Clinic

SUMMARY OF THE PRODUCT CHARACTERISTICS

Summary of Product Characteristics

Endocrine. Endocrine as it relates to the kidney. Sarah Elfering, MD University of Minnesota

Summary of Product Characteristics

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory OSTOCALCIUM TABLETS. Calcium and Phosphorus with Vitamin D3 Tablets

Persistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019

Calcium metabolism and the Parathyroid Glands. Calcium, osteoclasts and osteoblasts-essential to understand the function of parathyroid glands

B. Environmental Factors. a. The major risk factor to papillary thyroid cancer is exposure to ionizing radiation, during the first 2 decades of life.

Calcium (Ca 2+ ) mg/dl

Calcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD

David Bruyette, DVM, DACVIM

Amjad Bani Hani Ass.Prof. of Cardiac Surgery & Intensive Care FLUIDS AND ELECTROLYTES

LRI Children s Hospital

Excipient(s) with known effect: One tablet contains 1 mg aspartame (E951), 390 mg sorbitol (E420) and 0.7 mg sucrose

1. NAME OF THE MEDICINAL PRODUCT. Calciflex-D 3 Citron 500 mg/400 IU film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

CAL360 Tablets (Calcium citrate malate + Vitamin D3 )

Endocrine Regulation of Calcium and Phosphate Metabolism

Hyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012

Hypercalcaemia with undetectable parathormone levels

Hyperparathyroidism. When to Suspect, How to Diagnose, When and How to Intervene. Johanna A. Pallotta, MD, FACP, FACE

NEOPLASMS OF THE THYROID PATHOLOGY OF PARATHYROID GLANDS. BY: Shifaa Qa qa

SUMMARY OF PRODUCT CHARACTERISTICS. A 2.5ml single-dose bottle containing IU Cholecalciferol (equivalent to 625 micrograms vitamin D 3 )

Since the advent of multichannel serum chemistry

PRIMARY HYPERPARATHYROIDISM PRIMARY HYPERPARATHYROIDISM. Hyperparathyroidism Etiology. Common Complex Insidious Chronic Global Only cure is surgery

SUMMARY OF PRODUCT CHARACTERISTICS

Hypercalcemia may be detected incidentally. Practice CMAJ. Primary hyperparathyroidism. Primer. Key points. The case. What causes hypercalcemia?

Package Insert. D-Bright

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Woman, 66, With Persistent Abdominal and Back Pain

Acute renal failure and unknown cause hypercalcemia (case report)

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

DBL CALCIUM GLUCONATE INJECTION BP

Oncologic Emergencies

Clodronate BE/H/PSUR/001/001 October 2011 Agreed CSP

SUMMARY OF PRODUCT CHARACTERISTICS

When the level of calcium in the blood falls too low, the parathyroid glands secrete just enough PTH to restore the blood calcium level.

The Calcium Conundrum: When, What and How to Give Calcium in Pediatric CKD/ESRD

D MADE in EU Brochure Carbocal_UK.indd 1 13/05/14 17:48

Current Management of Metastatic Bone Disease

CCRN Review - Renal. CCRN Review - Renal 10/16/2014. CCRN Review Renal. Sodium Critical Value < 120 meq/l > 160 meq/l

New Zealand Data Sheet. Arrow-Bendrofluazide Bendroflumethiazide (also known as Bendrofluazide) Tablets 2.5mg and 5mg

Produktinformationen för Calcichew-D3 Citron, 1000 mg/800 IE tuggtablett, MTnr 26065, gäller vid det tillfälle då läkemedlet godkändes.

HYPERPARATHYROIDIS M FAISAL GHANI SIDDIQUI MBBS; FCPS; PGDIP-BIOMEDICAL ETHICS; MCPS-HPE

Case Report Letrozole Induced Hypercalcemia in a Patient with Breast Cancer

Hypoglycemia, Electrolyte disturbances and acid-base imbalances

Tymlos (abaloparatide) NEW PRODUCT SLIDESHOW

Article 30 Referral for Calcitugg (and associated names) Chewable tablets (Calcium carbonate)

Ca, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary

Pituitary, Parathyroid Pheochromocytomas & Paragangliomas: The 4 Ps of NETs

Hypoparathyroidism By John Halpern, DO, FACEP Coauthored by N. Ewen Wang, MD

W. Heath Giles, M.D. University of Tennessee College of Medicine Chattanooga Assistant Professor of Surgery Associate Residency Program Director

Magnesium Homeostasis

P1: IML/FFX P2: IML/FFX QC: IML/FFX T1: IML BY BY025-v2.cls June 30, : Blueprints Q&A Step 2 Medicine

WHAT IS YOUR DIAGNOSIS?

Primary Hyperparathyroidism

ECG & ELECTROLYTES IMBALANCE

DIAGNOSING X-LINKED HYPOPHOSPHATEMIA (XLH) BIOCHEMICAL TESTING CONSIDERATIONS

Electrolyte Emergencies

Calcium. Electrolyte quintet. Calcium homoeostasis

Parathyroid Disease Scenarios for the Practicing Clinician. Vijaya Chockalingam MD Faculty Endocrinologist Banner University Medical Center- Phoenix

Saint-Antoine Hospital, Paris. Medical Intensive Unit Care. Hafid Ait-Oufella, MD.PhD. Dyscalcemia. Dyskalemia

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Disclosure. Primary Hyperparathyroidism 4 th IW. Topic Outline. Calcium, Vitamin D, PTH Disorders. I have nothing to disclose related to this topic

PACKAGE LEAFLET: INFORMATION FOR THE USER. CALCICLO STEROP 11 meq 10 ml Solution for injection. Dihydrated Calcium Chloride

HYPERCALCEMIA, HYPOCALCEMIA, PARATHYROID DISORDERS. Dr. Csaba Horváth. 1st Department of Internal Medicine Semmelweis University Budapest

Transcription:

HYPERCALCEMIA Babak Tamizi Far MD. Assistant professor of internal medicine Al-zahra hospital, Isfahan university of medical sciences

ESSENTIALS OF DIAGNOSIS Serum calcium level > 10.5 mg/dl Serum ionized calcium > 5.3 mg/dl Primary hyperparathyroidism and malignancyassociated hypercalcemia are the most common causes Hypercalciuria usually precedes hypercalcemia Most often, asymptomatic, mild hypercalcemia ( 11 mg/dl) is due to primary hyperparathyroidism, whereas the symptomatic, severe hypercalcemia ( 14 mg/dl) is due to hypercalcemia of malignancy

GENERAL CONSIDERATIONS Primary hyperparathyroidism and malignancy account for 90% of cases Chronic hypercalcemia (over 6 months) or some other manifestations such as nephrolithiasis suggests a benign cause Tumor production of PTH-related proteins (PTHrP) is the most common paraneoplastic endocrine syndrome, accounting for most cases of hypercalcemia in inpatients

GENERAL CONSIDERATIONS Granulomatous diseases, such as sarcoidosis and tuberculosis, cause hypercalcemia from production of active vitamin D3 (1,25 dihydroxyvitamin D3) by the granulomas Milk-alkali syndrome has had a resurgence related to calcium ingestion for prevention of osteoporosis

Etiology Increased intake or absorption Milk-alkali syndrome Vitamin D or A excess Endocrine disorders Primary and secondary hyperparathyroidism Acromegaly Adrenal insufficiency Pheochromocytoma Thyrotoxicosis

Etiology Neoplastic diseases Tumor production of PTHrP (ovary, kidney, lung) Multiple myeloma (osteoclast-activating factor) Lymphoma

Etiology Miscellaneous causes Thiazide diuretics Granulomatous diseases Paget bone disease Hypophosphatasia Immobilization Familial hypocalciuric hypercalcemia Complications of kidney transplantation Lithium intake

Clinical Findings SYMPTOMS AND SIGNS May affect gastrointestinal, kidney, and neurologic function Mild hypercalcemia is often asymptomatic Symptoms usually occur if the serum calcium is > 12 mg/dl and tend to be more severe if hypercalcemia develops acutely

SYMPTOMS AND SIGNS Constipation and polyuria Polyuria is absent in hypocalciuric hypercalcemia Polyuria from hypercalciuria-induced nephrogenic diabetes insipidus can result in volume depletion and acute kidney injury

Other abdominal symptoms include Nausea Vomiting Anorexia Peptic ulcer disease Renal colic Hematuria from nephrolithiasis

Neurologic manifestations may range from mild drowsiness to weakness, depression, lethargy, stupor, and coma in severe cases Ventricular ectopy and idioventricular rhythm occur and can be accentuated by digitalis

Diagnosis LABORATORY TESTS Serum calcium level > 10.5 mg/dl Serum ionized calcium > 5.3 mg/dl The highest serum calcium levels ( 15 mg/dl) generally occur in malignancy A high serum chloride concentration and a low serum phosphate concentration (ratio > 33:1) suggest primary hyperparathyroidism because PTH decreases proximal tubular phosphate reabsorption

LABORATORY TESTS Urinary calcium excretion > 200 mg/day suggests hypercalciuria < 100 mg/day suggests hypocalciuria

LABORATORY TESTS Hypercalciuria from malignancy or from vitamin D therapy frequently results in hypercalcemia when volume depletion occurs Measurements of PTH and PTHrP levels help distinguish between hyperparathyroidism (elevated PTH) and malignancy-associated hypercalcemia (suppressed PTH and elevated PTHrP) Serum phosphate may or may not be low, depending on the cause

IMAGING STUDIES Chest radiograph: to exclude malignancy or granulomatous disease DIAGNOSTIC PROCEDURE ECG: shortened QT interval

Treatment: MEDICATIONS Emergency treatment Establish euvolemia to induce renal excretion of Na+, which is accompanied by excretion of Ca2+ In dehydrated patients with normal cardiac and renal function, infuse 0.45% saline or 0.9% saline rapidly (250 500 ml/h) Furosemide intravenously is often administered but its efficacy and safety were questioned in one meta-analysis

Emergency treatment Thiazides can actually worsen hypercalcemia (as can furosemide if inadequate saline is given

In the treatment of hypercalcemia of malignancy Bisphosphonates are the mainstay, although they may require up to 48 72 hours before reaching full therapeutic effect Calcitonin may be helpful to treat hypercalcemia before the onset of action of bisphosphonates

THERAPEUTIC PROCEDURES In emergency cases, dialysis with low or no calcium dialysate may be needed

Table 347-2 Guidelines for Parathyroid Surgery in Asymptomatic Primary Hyperparathyroidisma Measurement Guidelines, 1990 Guidelines, 2002 Serum calcium (above upper limit of normal) 0.3 0.4 mmol/l(1 1.5 mg/dl) above normal 0.3 mmol/l (1.0 mg/dl) above normal 24-h urinary calcium >400 mg >400 mg Creatinine clearance Reduced by 30% Reduced by 30% Bone mineral density Z-score <-2.0 (forearm) T-score <-2.5 at any site Age <50 <50

Outcome FOLLOW-UP Monitor serum calcium at least every 6 months during medical therapy of hyperparathyroidism

COMPLICATIONS Pathologic fractures Renal calculi Chronic kidney disease Peptic ulcer disease Pancreatitis Precipitation of calcium throughout the soft tissues Gestational hypercalcemia produces neonatal hypocalcemia

PROGNOSIS Depends on the underlying disease Poor prognosis in malignancy

PREVENTION Prevent dehydration that can further aggravate hypercalcemia

WHEN TO REFER Patients with malignancy-related hypercalcemia should be referred to an oncologist Patients with endocrine disorders should be referred to an endocrinologist Patients with granulomatous diseases (eg, tuberculosis and other chronic infections, Wegener granulomatosis, sarcoidosis) may require consultation with infectious disease specialists, rheumatologists, or pulmonologists

WHEN TO ADMIT Patients with symptomatic or severe hypercalcemia require immediate treatment Unexplained hypercalcemia with associated conditions, such as acute kidney injury or suspected malignancy, may also require hospitalization for treatment and expedited evaluation

The End